Transparency of reporting in molecular diagnostics

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 15878-15884

  Bustin, Stephen ^a  

^a ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; NANOPARTICLE;

BIOASSAY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC PURITY; GENETIC SCREENING; GOLD STANDARD; HEALTH CARE COST; HIGH RESOLUTION MELT ANALYSIS; HUMAN; ISOTHERMAL AMPLIFICATION; MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY;

EPIGENOMICS; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; NUCLEIC ACIDS; PATHOLOGY, MOLECULAR; POLYMERASE CHAIN REACTION; RNA;

EID: 84881123147     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140815878     Document Type: Editorial

References (59)

1. Chan, S.Y.; Loscalzo, J. The emerging paradigm of network medicine in the study of human disease. Circ. Res. 2012, 111, 359-374.
2. Katsanis, S.H.; Katsanis, N. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 2013, 14, 415-426.
3. La Thangue, N.B.; Kerr, D.J. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8, 587-596.
4. Muldrew, K.L. Molecular diagnostics of infectious diseases. Curr. Opin. Pediatr. 2009, 21, 102-111.
5. Dong, J.; Olano, J.P.; McBride, J.W.; Walker, D.H. Emerging pathogens: Challenges and successes of molecular diagnostics. J. Mol. Diagn. 2008, 10, 185-197.
6. Deschoolmeester, V.; Baay, M.; Specenier, P.; Lardon, F.; Vermorken, J.B. A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy. Oncologist 2010, 15, 699-731.
7. Chehab, F.F. Molecular diagnostics: Past, present, and future. Hum. Mutat. 1993, 2, 331-337.
8. Simon, R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per. Med. 2010, 7, 33-47.
9. Bustin, S.A.; Murphy, J.; Kessler, H.H. Amplification and Detection Methods. In Molecular Diagnostics of Infectious Diseases; Kessler, H.H., Ed.; De Gruyter: Berlin, Germany, 2012; pp. 53-68.
10. Su, Z.; Ning, B.; Fang, H.; Hong, H.; Perkins, R.; Tong, W.; Shi, L. Next-generation sequencing and its applications in molecular diagnostics. Expert Rev. Mol. Diagn. 2011, 11, 333-343.
11. Heideman, D.A.; Lurkin, I.; Doeleman, M.; Smit, E.F.; Verheul, H.M.; Meijer, G.A.; Snijders, P.J.; Thunnissen, E.; Zwarthoff, E.C. KRAS and BRAF mutation analysis in routine molecular diagnostics: Comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J. Mol. Diagn. 2012, 14, 247-255.
12. Jordan, B.R. Is there a niche for DNA microarrays in molecular diagnostics? Expert Rev. Mol. Diagn. 2010, 10, 875-882.
13. Mohapatra, G.; Betensky, R.A.; Miller, E.R.; Carey, B.; Gaumont, L.D.; Engler, D.A.; Louis, D.N. Glioma test array for use with formalin-fixed, paraffin-embedded tissue: Array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J. Mol. Diagn. 2006, 8, 268-276.
14. Ganova-Raeva, L.M.; Khudyakov, Y.E. Application of mass spectrometry to molecular diagnostics of viral infections. Expert Rev. Mol. Diagn. 2013, 13, 377-388.
15. Leigh, S.Y.; Som, M.; Liu, J.T. Method for assessing the reliability of molecular diagnostics based on multiplexed SERS-coded nanoparticles. PLoS One 2013, 8, e62084.
16. Horbinski, C.; Miller, C.R.; Perry, A. Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol. 2011, 21, 57-73.
17. Bustin, S.A.; Mueller, R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin. Sci. (Lond.) 2005, 109, 365-379.
18. Savaryn, J.P.; Catherman, A.D.; Thomas, P.M.; Abecassis, M.M.; Kelleher, N.L. The emergence of top-down proteomics in clinical research. Genome Med. 2013, 5, 53.
19. Baudhuin, L.M.; Donato, L.J.; Uphoff, T.S. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev. Mol. Diagn. 2012, 12, 25-37.
20. Josko, D. Molecular virology in the clinical laboratory. Clin. Lab. Sci. 2010, 23, 231-236.
21. Afshari, A.; Pagani, L.; Harbarth, S. Year in review 2011: Critical care-Infection. Crit. Care 2012, 16, 242.
22. Reinhart, K.; Bauer, M.; Riedemann, N.C.; Hartog, C.S. New approaches to sepsis: Molecular diagnostics and biomarkers. Clin. Microbiol. Rev. 2012, 25, 609-634.
23. Krishna, N.K.; Cunnion, K.M. Role of molecular diagnostics in the management of infectious disease emergencies. Med. Clin. North Am. 2012, 96, 1067-1078.
24. Normanno, N.; Rachiglio, A.M.; Roma, C.; Fenizia, F.; Esposito, C.; Pasquale, R.; La Porta, M.L.; Iannaccone, A.; Micheli, F.; Santangelo, M.; et al. Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. J. Cell. Biochem. 2013, 114, 514-524.
25. Desiere, F.; Romano Spica, V. Personalised medicine in 2012: Editorial to the special issue of New Biotechnology on "molecular diagnostics & personalised medicine". New Biotechnol. 2012, 29, 611-612.
26. Petak, I.; Schwab, R.; Orfi, L.; Kopper, L.; Keri, G. Integrating molecular diagnostics into anticancer drug discovery. Nat. Rev. Drug Discov. 2010, 9, 523-535.
27. Bedeir, A.; Krasinskas, A.M. Molecular diagnostics of colorectal cancer. Arch. Pathol. Lab. Med. 2011, 135, 578-587.
28. Heaney, N.B.; Holyoake, T.L. Therapeutic targets in chronic myeloid leukaemia. Hematol. Oncol. 2007, 25, 66-75.
29. Ashman, L.K.; Griffith, R. Therapeutic targeting of c-KIT in cancer. Expert Opin. Investig. Drugs 2013, 22, 103-115.
30. Radvansky, J.; Ficek, A.; Kadasi, L. Upgrading molecular diagnostics of myotonic dystrophies: Multiplexing for simultaneous characterization of the DMPK and ZNF9 repeat motifs. Mol. Cell. Probes 2011, 25, 182-185.
31. Dai, R.; Ahmed, S.A. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl. Res. 2011, 157, 163-179.
32. Bustin, S.A. Why the need for qPCR publication guidelines?-The case for MIQE. Methods 2010, 50, 217-226.
33. Bustin, S.A. Real-time polymerase chain reaction-Towards a more reliable, accurate and relevant assay. Eur. Pharmeceutical Rev. 2008, 6, 19-27.
34. Bustin, S. Molecular medicine, gene-expression profiling and molecular diagnostics: Putting the cart before the horse. Biomark. Med. 2008, 2, 201-207.
35. Murphy, J.; Dorudi, S.; Bustin, S.A. Molecular staging of colorectal cancer: New paradigm or waste of time? Expert Opin. Med. Diagn. 2007, 1, 31-45.
36. Bustin, S.A. Nucleic acid quantification and disease outcome prediction in colorectal cancer. Pers. Med. 2006, 3, 207-216.
37. Bustin, S.A. Real-time, fluorescence-based quantitative PCR: A snapshot of current procedures and preferences. Expert Rev. Mol. Diagn. 2005, 5, 493-498.
38. Bustin, S.A.; Benes, V.; Nolan, T.; Pfaffl, M.W. Quantitative real-time RT-PCR-A perspective. J. Mol. Endocrinol. 2005, 34, 597-601.
39. Bustin, S.A.; Nolan, T. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J. Biomol. Tech. 2004, 15, 155-166.
40. Bustin, S.A. Meaningful Quantification of mRNA Using Real-time PCR. In PCR Technology Current Innovations; Griffin, T.W.H.G.G.A., Ed.; CRC Press: Boca Raton, FL, USA, 2004; pp. 225-233.
41. Bustin, S.A.; Nolan, T. Basic RT-PCR Considerations. In A-Z of Quantitative PCR; Bustin, S.A., Ed.; IUL Press: La Jolla, CA, USA, 2004; pp. 359-396.
42. Bustin, S.A. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J. Mol. Endocrinol. 2002, 29, 23-39.
43. Bustin, S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000, 25, 169-193.
44. Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L.; et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55, 611-622.
45. Huggett, J.F.; Foy, C.A.; Benes, V.; Emslie, K.; Garson, J.A.; Haynes, R.; Hellemans, J.; Kubista, M.; Mueller, R.D.; Nolan, T.; et al. The digital MIQE guidelines: Minimum information for publication of quantitative digital PCR experiments. Clin. Chem. 2013, 59, 892-902.
46. Anonymous Announcement: Reducing our irreproducibility. Nature 2013, 496, 398.
47. Bustin, S.A.; Beaulieu, J.F.; Huggett, J.; Jaggi, R.; Kibenge, F.S.; Olsvik, P.A.; Penning, L.C.; Toegel, S. MIQE precis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol. Biol. 2010, 11, 74.
48. Bustin, S.; Penning, L.C. Improving the analysis of quantitative PCR data in veterinary research. Vet. J. 2012, 191, 279-281.
49. Chagovetz, A.; Blair, S. Real-time DNA microarrays: Reality check. Biochem. Soc. Trans. 2009, 37, 471-475.
50. Paul, D.; Kumar, A.; Gajbhiye, A.; Santra, M.K.; Srikanth, R. Mass spectrometry-based proteomics in molecular diagnostics: Discovery of cancer biomarkers using tissue culture. Biomed. Res. Int. 2013, 2013, 783131.
51. Fleige, S.; Pfaffl, M.W. RNA integrity and the effect on the real-time qRT-PCR performance. Mol. Asp. Med. 2006, 27, 126-139.
52. Nolan, T.; Hands, R.E.; Ogunkolade, B.W.; Bustin, S.A. SPUD: A qPCR assay for the detection of inhibitors in nucleic acid preparations. Anal. Biochem. 2006, 351, 308-310.
53. Schroeder, A.; Mueller, O.; Stocker, S.; Salowsky, R.; Leiber, M.; Gassmann, M.; Lightfoot, S.; Menzel, W.; Granzow, M.; Ragg, T. The RIN: An RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 2006, 7, 3.
54. Nolan, T.; Hands, R.E.; Bustin, S.A. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 2006, 1, 1559-1582.
55. Huggett, J.; Dheda, K.; Bustin, S.; Zumla, A. Real-time RT-PCR normalisation; strategies and considerations. Genes Immun. 2005, 6, 279-284.
56. Vandesompele, J.; de Preter, K.; Pattyn, F.; Poppe, B.; van Roy, N.; de Paepe, A.; Speleman, F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3, 0034:1-0034:11.
57. Peltier, H.J.; Latham, G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14, 844-852.
58. Chang, K.H.; Mestdagh, P.; Vandesompele, J.; Kerin, M.J.; Miller, N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010, 10, 173.
59. Draghici, S.; Khatri, P.; Eklund, A.C.; Szallasi, Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet. 2006, 22, 101-109.